Renovaro Inc. (NASDAQ:RENB), a pharmaceutical preparations company, has announced the appointment of Nathen Fuentes as its new Chief Financial Officer effective January 6, 2025.
Fuentes, 42, brings extensive experience from various senior strategic, operational, and financial leadership roles in the biotechnology and specialty healthcare sectors.
Prior to joining Renovaro, Fuentes served as CFO at Telomir Pharmaceuticals, focusing on age-reversal science, and held similar positions at Emergence Health Holdings, Divergent Dental Group, Family First Homecare, and Dermatology Medical (TASE:PMCN) Partners. His early career included a stint as an Experienced Associate at PricewaterhouseCoopers and managerial roles in homebuilding companies. Fuentes, a Certified Public Accountant, holds a Bachelor of Science in marketing from the University of Florida and a Master of Science in accounting from Fairfield University.
Under the terms of the employment agreement, Fuentes will receive an annual base salary of $280,000 and is eligible for a performance bonus of up to $40,000, payable by March 15 each year. For the 2025 calendar year, he will receive a pro-rated bonus. Additionally, he has been granted 250,000 stock options, vesting quarterly over two years, and may receive a discretionary equity grant on his first employment anniversary.
Fuentes is entitled to the company’s standard employee benefits and reasonable business expense reimbursements. In case of termination without cause or resignation for good reason, including a significant sale or merger where the company's shareholders lose control, Fuentes will receive six months of his base salary, COBRA premium reimbursements for six months, and accelerated vesting of equity awards as severance.
Simon Tarsh, previously serving as Interim Chief Financial Officer, has been removed from his position in conjunction with Fuentes' appointment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.